Synapse - Works

Results (4925)

Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL): CHRONOS-3 and CHRONOS-4

Meeting Abstract

Gerecitano, J.; Zheng, H.; Mongay Soler, L.; Ito, R.; Reis, D.; Lu, C.; Shen, J.; Childs, B. H.; Zinzani, P. L.
Annals of Oncology (2017)

Fulltext@MSK | Save

Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)

Meeting Abstract

Hecht, J. R.; Naing, A.; Falchook, G.; Patel, M. R.; Infante, J. R.; Aljumaily, R.; Wong, D. J.; Autio, K.; Wainberg, Z. A.; Javle, M.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial

Meeting Abstract

de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; Necchi, A.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice

Meeting Abstract

Delaloge, S.; Conte, P. F.; Im, S. A.; Senkus-Konefka, E.; Xu, B.; Domchek, S. M.; Masuda, N.; Li, W.; Tung, N.; Armstrong, A.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers

Meeting Abstract

Diaz, L.; Marabelle, A.; Kim, T. W.; Geva, R.; Van Cutsem, E.; André, T.; Ascierto, P. A.; Maio, M.; Delord, J. P.; Gottfried, M.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

A phase 1 study of oral LOXO 292 in adult patients with advanced solid tumors, including RET-fusion non-small cell lung cancer, medullary thyroid cancer and other tumors with increased RET activity

Meeting Abstract

Drilon, A. E.; Bauer, T. M.; Subbiah, V.; Cabanillas, M.; Lahkani, N.; Wirth, L.; Oxnard, G.; Smith, S.; Eary, T.; Cruickshank, S.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Co-amplification of KIT/KDR/PDGRA in over 100,000 advanced cancer cases

Meeting Abstract

Disel, U.; Madison, R.; Chung, J.; Gounder, M.; Oztan, A.; Benson, A.; Webster, J.; Klempner, S. J.; Ou, S. H. I.; Ganesan, S.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC

Meeting Abstract

Drilon, A. E.; Liu, S.; Doebele, R.; Rodriguez, C.; Fakih, M.; Reckamp, K. L.; Bazhenova, L.; Cho, B. C.; Kowack, E.; Oliver, J.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Results of a randomized, placebo-controlled, phase 2 study of tarex-tumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

Meeting Abstract

Daniel, D. B.; Rudin, C. M.; Hart, L.; Spigel, D. R.; Edelman, M. J.; Goldschmidt, J.; Bordoni, R.; Glisson, B.; Burns, T. F.; Dowlati, A.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients

Meeting Abstract

Bixby, D.; Vigil, C. E.; Jurcic, J.; Cook, R.; Sekeres, M. A.; Rizzieri, D.; Cortes, J.; Redner, R.; Steensma, D.; Roboz, G.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save